Entrada Therapeutics Inc (TRDA) — Strategic Asset Allocation Index
Entrada Therapeutics Inc (TRDA) has a Strategic Asset Allocation Index of 48.0% as of June 2023. Strategic assets (PP&E of $99.30 Million plus long-term investments of $-) total $99.30 Million, measured against net assets of $206.91 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see TRDA company net worth.
SAAI
Strategic Assets
PP&E
Net Assets
Entrada Therapeutics Inc Strategic Asset Allocation Index (2021–2022)
This chart shows how Entrada Therapeutics Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 48.0%, representing strategic assets of $99.30 Million against net assets of $206.91 Million USD. See net asset quality index of Entrada Therapeutics Inc to measure how much of total assets are equity-financed.
Annual Strategic Asset Allocation Index for Entrada Therapeutics Inc (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Entrada Therapeutics Inc from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore Entrada Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 15.5% | $33.02 Million | $33.02 Million | $- | $212.55 Million | ▲ +13.4 pp |
| 2021 | 2.1% | $6.26 Million | $6.26 Million | $- | $298.72 Million | — |